Jiangsu Gdk Biological Technology Co., Ltd (SHA:688670)
China · Delayed Price · Currency is CNY 19.70
-0.11 (-0.56%)
Feb 13, 2026, 3:00 PM CST
SHA:688670 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 116.56 | 80.8 | 134.59 | 318.49 | 390.56 | 589.1 |
Other Revenue | - | - | - | - | 1.71 | - |
| 116.56 | 80.8 | 134.59 | 318.49 | 392.27 | 589.1 | |
Revenue Growth (YoY) | 121.40% | -39.96% | -57.74% | -18.81% | -33.41% | 777.27% |
Cost of Revenue | 64.3 | 51.87 | 86.29 | 87.41 | 114.52 | 76.47 |
Gross Profit | 52.26 | 28.93 | 48.3 | 231.07 | 277.75 | 512.63 |
Selling, General & Admin | 147.87 | 117.06 | 134.1 | 166.35 | 163.09 | 255.38 |
Research & Development | 59.71 | 33.61 | 15.47 | 32.41 | 35.26 | 28.53 |
Other Operating Expenses | 1.74 | 1.93 | 1.35 | 2.84 | 3.56 | 3.6 |
Operating Expenses | 213.77 | 155.27 | 139.66 | 202.75 | 203.18 | 303.09 |
Operating Income | -161.5 | -126.34 | -91.36 | 28.32 | 74.58 | 209.54 |
Interest Expense | -1.3 | -1.6 | -1.9 | -1.28 | -9.85 | -9.64 |
Interest & Investment Income | 7.76 | 13.04 | 15.15 | 17.53 | 7.69 | 0.67 |
Currency Exchange Gain (Loss) | - | - | - | 0 | - | - |
Other Non Operating Income (Expenses) | -2.9 | -3.81 | -0.9 | -0.02 | -0.01 | -0.02 |
EBT Excluding Unusual Items | -157.95 | -118.71 | -79.01 | 44.55 | 72.4 | 200.55 |
Gain (Loss) on Sale of Investments | -0.15 | 0.17 | -0.15 | -1.74 | 2.31 | - |
Gain (Loss) on Sale of Assets | -0.11 | -0.1 | - | 0.23 | -0.05 | 0 |
Asset Writedown | -6.79 | -0.88 | -0.24 | -3.29 | -3.75 | - |
Other Unusual Items | 3.77 | 3.77 | -7.18 | 8.66 | 13.09 | 10.37 |
Pretax Income | -161.22 | -115.75 | -86.57 | 48.41 | 84 | 210.93 |
Income Tax Expense | -34.71 | -22.25 | -15.58 | 6.86 | 1.54 | 55.95 |
Net Income | -126.51 | -93.5 | -70.99 | 41.54 | 82.46 | 154.98 |
Net Income to Common | -126.51 | -93.5 | -70.99 | 41.54 | 82.46 | 154.98 |
Net Income Growth | - | - | - | -49.62% | -46.79% | - |
Shares Outstanding (Basic) | 122 | 123 | 122 | 122 | 105 | 92 |
Shares Outstanding (Diluted) | 122 | 123 | 122 | 122 | 105 | 92 |
Shares Change (YoY) | -0.73% | 0.52% | 0.17% | 16.43% | 13.67% | 31.62% |
EPS (Basic) | -1.03 | -0.76 | -0.58 | 0.34 | 0.79 | 1.68 |
EPS (Diluted) | -1.03 | -0.76 | -0.58 | 0.34 | 0.79 | 1.68 |
EPS Growth | - | - | - | -56.73% | -53.19% | - |
Free Cash Flow | -186.95 | -169.86 | 26.9 | -129.58 | -282.46 | 68.65 |
Free Cash Flow Per Share | -1.53 | -1.38 | 0.22 | -1.06 | -2.69 | 0.74 |
Dividend Per Share | - | - | - | 0.143 | 0.357 | - |
Dividend Growth | - | - | - | -59.98% | - | - |
Gross Margin | 44.84% | 35.80% | 35.89% | 72.55% | 70.81% | 87.02% |
Operating Margin | -138.56% | -156.35% | -67.88% | 8.89% | 19.01% | 35.57% |
Profit Margin | -108.54% | -115.72% | -52.74% | 13.04% | 21.02% | 26.31% |
Free Cash Flow Margin | -160.39% | -210.22% | 19.99% | -40.69% | -72.01% | 11.65% |
EBITDA | -133.48 | -97.52 | -61.49 | 58.08 | 102.65 | 235.35 |
EBITDA Margin | -114.51% | -120.69% | -45.68% | 18.24% | 26.17% | 39.95% |
D&A For EBITDA | 28.03 | 28.82 | 29.87 | 29.76 | 28.08 | 25.81 |
EBIT | -161.5 | -126.34 | -91.36 | 28.32 | 74.58 | 209.54 |
EBIT Margin | -138.56% | -156.35% | -67.88% | 8.89% | 19.01% | 35.57% |
Effective Tax Rate | - | - | - | 14.18% | 1.83% | 26.52% |
Revenue as Reported | 116.56 | 80.8 | 134.59 | 318.49 | 392.27 | 589.1 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.